ARQIS advises Central Glass on sale of German subsidiary to Evotec

25. August 2022

ARQIS has advised the listed Japanese chemical manufacturing company Central Glass Co. Ltd. on the sale of Central Glass Germany GmbH in Halle/Westphalia to Evotec SE.

Central Glass Germany is located on a pharmaceutical manufacturing campus in Halle/Westphalia, Germany and has a team of approximately 60 chemical manufacturing experts. The facility is EU cGMP certified and provides highly flexible drug substance manufacturing space with over 5,000 square meters of floor space. The transaction is subject to customary closing conditions and anticipated to close on 1 November 2022.

The ARQIS team around Shigeo Yamaguchi has a long-standing relationship with Central Glass Co. Ltd. ARQIS already advised Central Glass Co. Ltd. in 2008 on the acquisition of the respective business and production facility in Halle from Girindus AG.


Berater Central Glass Co. Ltd.

ARQIS (Dusseldorf): Dr. Shigeo Yamaguchi (Lead), Eberhard Hafermalz (both Corporate/M&A), Dr. Mauritz von Einem (Tax; Munich), Dr. Hendrik von Mellenthin (Labour Law), Dr. Ulrich Lienhard (Real Estate), Dr. Friedrich Gebert (Public Law/Regulatory), Marcus Nothhelfer (IP; Munich), Tobias Neufeld (Data.Law), Johannes Landry (Restructuring), Dimitrios Christopoulos (Insurance); Counsels: Dr. Deniz Günal (Corporate/M&A), Jens Knipping (Tax); Associates: Kiyomi Katrin Zimmer (Corporate/M&A), Dr. Hanna Caesar (Labour Law), Daniel Schlemann (Data.Law), Rolf Tichy (IP; Munich); Legal Specialists: Miho Kuramochi (Corporate/M&A), Julia Regenauer (Pensions)


If you have any questions, please write to us.